SEC Company Response from Cocrystal Pharma, Inc. (COCP) (CIK 0001412486) (COCP) — Sep 21, 2012
Cocrystal Pharma, Inc. (COCP) (CIK 0001412486)
Date: Sept. 21, 2012 · CIK: 0001412486 · Accession: 0001521536-12-000957
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-176951
Referenced dates: July 25, 2012
Letter
United States Securities and Exchange Commission Division of Corporation Finance Re: Biozone Pharmaceuticals, Inc. (the “Company”) Amendment No. 2 to Registration Statement on Form S-1 Filed July 2, 2012 File No. 333-176951
Dear Sir/Madam,
The Company hereby respectfully requests an extension to respond to the comment letter dated July 25, 2012 relating to the above-referenced filing and the Company intends to submit a response by September 28, 2012.
Very Truly Yours,
/s/ Elliot Maza
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
BIOZONE PHARMACEUTICALS, INC.
550 Sylvan Avenue, Suite 101
Engelwood Cliffs, NJ 07632
September 21, 2012
BY EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Jennifer Riegel
Jeffrey P. Riedler
Re:
Biozone Pharmaceuticals, Inc. (the “Company”)
Amendment No. 2 to Registration Statement on Form S-1
Filed July 2, 2012
File No. 333-176951
Dear Sir/Madam,
The Company hereby respectfully requests an extension to respond to the comment letter dated July 25, 2012 relating to the above-referenced filing and the Company intends to submit a response by September 28, 2012.
Very Truly Yours,
/s/ Elliot Maza
Elliot Maza
Chief Executive Officer and Chief Financial Officer